Sarepta 1st Phase 1/2 data supporting αvβ6 integrin-targeted siRNA muscle delivery platform
Sarepta unveils first Phase 1/2 data for SRP-1001 and SRP-1003 supporting αvβ6 integrin-targeted siRNA muscle delivery platform
- SRP-1001 is being developed for FSHD1 and SRP-1003 for DM1 in Phase 1/2 studies.
- Initial clinical data show dose-dependent muscle exposure and target knockdown for both siRNA candidates.
- Both candidates demonstrated favorable tolerability, supporting Sarepta's αvβ6 integrin-targeted delivery platform for muscle.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.